Diamond Therapeutics Announces Health Canada Approval of Clinical Trial with Low-Dose Psilocybin
- Tuesday, August 17, 2021, 7:12
- Finance
- Add a comment
TORONTO, Aug. 17, 2021 /PRNewswire/ – Diamond Therapeutics Inc. (“Diamond”), a drug development company focused on low-dose psychedelic therapies for use in the treatment of mental health, is pleased to announce that it has received a No Objection Letter from Health Canada, allowing…
About the Author
adminasapcorp has written 41811 stories on this site.